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Abstract
Background: Upon CD95/Fas ligation, the initiator caspase-8 is known to activate effector caspases leading to apoptosis. In
the presence of zVAD-fmk, a broad-spectrum caspase inhibitor, Fas engagement can also trigger an alternative, non-
apoptotic caspase-independent form of cell death, which is initiated by RIP1. Controversy exists as to the ability of caspase-
10 to mediate cell death in response to FasL (CD95L or CD178). Herein, the role of caspase-10 in FasL-induced cell death has
been re-evaluated.
Methodology and Principal Findings: The present study shows that FasL-induced cell death was completely impaired in
caspase-8- and caspase-10-doubly deficient (I9-2e) Jurkat leukaemia T-cell lines. Over-expressing of either caspase-8 or
caspase-10 in I9-2e cells triggered cell death and restored sensitivity to FasL, further arguing for a role of both initiator
caspases in Fas apoptotic signalling. In the presence of zVAD-fmk, FasL triggered an alternative form of cell death similarly in
wild-type (A3) and in caspase-8-deficient Jurkat cells expressing endogenous caspase-10 (clone I9-2d). Cell death initiated
by Fas stimulation in the presence of zVAD-fmk was abrogated in I9-2e cells as well as in HeLa cells, which did not express
endogenous caspase-10, indicating that caspase-10 somewhat participates in this alternative form of cell death.
Noteworthy, ectopic expression of caspase-10 in I9-2e and HeLa cells restored the ability of FasL to trigger cell death in the
presence of zVAD-fmk. As a matter of fact, FasL-triggered caspase-10 processing still occurred in the presence of zVAD-fmk.
Conclusions and Significance: Altogether, these data provide genetic evidence for the involvement of initiator caspase-10
in FasL-induced cell death and indicate that zVAD-fmk does not abrogate caspase-10 processing and cytotoxicity in Fas
signalling. Our study also questions the existence of an alternative caspase-independent cell death pathway in Fas
signalling.
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Introduction
Fas (CD95 or Apo-1) is a member of the TNF (tumour necrosis
factor) receptor superfamily. Fas plays a crucial function in the
regulation of T-cell homeostasis as illustrated by the development
of an autoimmune lymphoproliferative syndrome (ALPS) in
patients carrying gene mutations affecting Fas signalling [1,2,3].
Upon FasL (CD95L or CD178) challenge, the adaptor protein
FADD (Fas-associated protein with death domain) is recruited to
the Fas death domain [4]. FADD next interacts with caspase-8 [5]
and -10 [6] to form the death-inducing signalling complex (DISC).
Oligomerization of caspase-8 and -10 at the DISC level is
responsible for the activation of the caspase cascade leading to
apoptosis [5,6]. Caspase-8 and -10 cleave and activate effector
caspase-3 and -7 [7,8,9], which in turn specifically cleave and
inactivate a variety of substrates essential for survival leading to
apoptosis [10]. Initiator caspases can trigger an alternative route of
cell death involving mitochondria. This pathway requires the
cleavage of Bid (Bcl-2 interacting domain), a pro-apoptotic
member of the Bcl-2 superfamily [11,12,13,14]. FasL has also
been reported to activate a caspase-independent cell death
pathway, leading to necrosis rather than apoptosis [15,16]. This
alternative pathway involves FADD and the kinase activity of RIP
(receptor-interacting protein), which is recruited to the Fas
receptor [15,16].
Caspase-8 and -10 can display non-apoptotic functions in cell
signalling [17]. Moreover, initiator caspase-8 and -10 have been
previously reported to activate signalling pathways independently
of their catalytic activities. For instance, over-expression of the N-
terminal part of caspase-8 containing the two death effector
domains (DED) but lacking the catalytic site, triggered death-
effector filament formation, leading to endogenous caspase
activation and apoptosis in HeLa cells [18]. The DED of
caspase-8 and -10 can activate NF-kB in a RIP-dependent
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large and small protease subunits, has been recently reported to
interact with RIP, activate NF-kB and induce cell death in the
absence of PARP [poly(ADP-Ribose)polymerase] cleavage [20].
Whereas the involvement of caspase-8 in FasL-triggered
apoptosis is well established, that of caspase-10 still remains a
matter of debate. Indeed, overexpression of caspase-10 comple-
mented caspase-8 deficiency in FasL-treated Jurkat cells in two
independent studies [9,21], but not in another [22]. The latter
study concluded that caspase-10 is indeed recruited to the DISC in
response to TRAIL or FasL but cannot functionally substitute
caspase-8 [22].
The present study was undertaken to further evaluate the
function of initiator caspase-10 in FasL-induced cell death. Our
data demonstrate that (i) FasL-induced cell death is abrogated in
caspase-8- and -10-doubly deficient Jurkat cells (I9-2e clone), but
not in caspase-8-deficient Jurkat cells expressing caspase-10 (I9-2d
clone); (ii) expression of wild-type caspase-10 can restore the ability
of FasL to trigger cell death in I9-2e cells; (iii) zVAD-fmk does not
impede FasL-induced caspase-10 processing and cytotoxicity.
Results
FasL-induced apoptosis is impaired in Jurkat cells
doubly-deficient for caspase-8 and -10
To characterize the Jurkat variants, I9-2a, b, d and e derived
from I9-2 cells, the expression of proteins involved in Fas signalling
was investigated. As expected from previous observations [13,23],
I9-2a, b, d and e cells did not express caspase-8 in contrast to A3
cells. However, FADD, RIP, caspase-2, -9, -3 and -7 (Fig. 1A) and
Fas/CD95 (Fig. 1B) were equally expressed in A3 and in the I9-2
variants. Importantly, whereas caspase-10 was expressed in A3, I9-
2d cells and, albeit to a lesser extent, I9-2b cells, barely detectable
expression of caspase-10 was found in I9-2a and e cells (Fig. 1A).
When the different cell variants were incubated in the presence of
FasL, toxicity was observed in A3 cells and, albeit to a lesser
extent, in I9-2b and I9-2d cells (Fig. 1C). In sharp contrast, FasL-
induced cell death was totally abrogated in the caspase-8 and -10-
doubly deficient I9-2a and e cells (Fig. 1C). Accordingly, FasL
induced caspase activation, as evaluated by the cleavage of the
effector caspase substrate Ac-DEVD-AMC and the initiator
Figure 1. Impairment of FasL-induced cell death in caspase-8 and -10-doubly deficient Jurkat cells. A,2 0mg total protein extracts from
parental (A3) and caspase-8 deficient (I9-2a, b, d and e) Jurkat cell lines were subjected to SDS-PAGE, and Western blotted with anti-caspase-8, -10, -2,
-9, -3, -7, anti-FADD, anti-RIP or anti-b-actin antibodies. B, Jurkat cells were labelled with anti-CD95-PE antibody (thick line) or an isotype control (thin
line) and analysed by flow cytometry. Percentages of cells expressing CD95 are indicated. C, Jurkat cells were incubated for 8 hours in the presence of
500 ng/mL FasL and cell viability was evaluated by MTT assay. Values are means 6 SEM of three independent experiments. *p,0.05; **p,0.01, ***
p,0.001 as compared to values obtained in A3 cells.
doi:10.1371/journal.pone.0013638.g001
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evaluated by flow cytometry (Figs. 2B and C), in A3 cells and,
albeit to a lesser extent, in I9-2d cells. FasL totally failed to trigger
caspase activation and apoptosis in I9-2e cells (Fig. 2). Identical
data have been found using the other caspase-8 and -10-doubly
deficient cells (i.e., I9-2a). These data are consistent with our
previous study indicating the involvement of both endogenous
caspase-8 and -10 in FasL-induced apoptosis [13].
Over-expression of caspase-8 or -10 restores FasL-
induced apoptosis in I9-2e cells
Experiments were next restricted to I9-2e cells, which do not
express endogenous caspase-8 and -10 (see Fig. 1A and [13]).
Over-expression of EGFP, an irrelevant protein in cell death
signalling, was used as a negative control to evaluate the basal
cytotoxicity induced in our experimental settings. Cells were
transfected with plasmids encoding EGFP-tagged wild-type or
catalytically inactive caspase-8 (C360S). Alternatively, cells were
transfected with a plasmid encoding EGFP-tagged wild-type
caspase-10 or co-transfected with plasmids encoding EGFP and
untagged catalytically inactive caspase-10 (C401S). Twelve hours
post-transfection, cells were further incubated for 4 hours in the
presence or absence of FasL (Fig. 3A). Cells were next labelled
with annexin-V-APC and analyses were restricted to the EGFP-
positive (i.e., transfected) cells. At least 1,000 EGFP-positive cells
were analyzed. As compared to EGFP alone expression, ectopic
expression of either wild-type caspase-8 or -10 strongly enhanced
annexin-V labelling (Fig. 3B), which was further increased upon
FasL treatment (Figs. 3B and C). Annexin-V labelling was slightly
increased when cells expressed the catalytically inactive caspase
mutants (Fig. 3B). However, mutants failed to significantly
sensitize cells to FasL (Fig. 3C). Altogether, our data further
indicate that both initiator caspase-8 and -10 are involved in FasL-
induced apoptosis.
FasL-induced cell death in the presence of zVAD-fmk is
impaired in Jurkat cells doubly deficient for caspase-8
and -10
In wild-type Jurkat cells, FasL-triggered caspase activation was
fully abrogated by the addition of 40 mM zVAD-fmk to the cell
culture medium (Fig. 4A). However, cell death, as evaluated both
by microscopy (Fig. 4B) and flow cytometry (Fig. 4C) analyses, still
occurred in the presence of zVAD-fmk. Microscopic analysis after
DAPI staining indicates that, in the absence of zVAD-fmk, FasL
elicited apoptosis in A3 cells as illustrated by strong nuclear
condensation and/or fragmentation (Fig. 4B). In the presence of
zVAD-fmk, dying cells displayed distinct nuclear features such as
partial chromatin condensation in the absence of nuclear
shrinkage, suggesting that FasL-triggered an alternative form of
cell death (Fig. 4B). Flow cytometry experiments indicate that most
Figure 2. Impairment of FasL-induced caspase activation and apoptosis in caspase-8 and -10-doubly deficient Jurkat cells. A, B,A 3
(white bars), I9-2d (grey bars) and I9-2e (black bars) Jurkat cells were incubated for 8 hours in the presence or absence of 500 ng/mL FasL as
indicated. Caspase activities were assessed using Ac-DEVD-AMC or Ac-IETD-AMC (A). Cells were stained with annexin-V-FITC and propidium iodide
and analyzed by flow cytometry. Percentages of annexin-V-positive (AnV+) are indicated (B). All data are means 6 SEM of three to four independent
experiments. *p,0.05; **p,0.01, *** p,0.001. C, Representative flow cytometry experiment. Low right quadrants: percentages of [AnV-FITC+
propidium iodide (PI)-] cells; Up right quadrants: percentages of [AnV-FITC+ PI+] cells; Up left quadrants: percentages of [AnV-FITC- PI+] cells.
doi:10.1371/journal.pone.0013638.g002
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propidium iodide (Fig. 4C). Whereas I9-2d cells, which express
caspase-10, died to a similar extent as A3 cells in the presence of
zVAD-fmk, I9-2e cells remained completely resistant to FasL
(Figs. 4B, C and D). Altogether, these results highlight the putative
role of endogenous initiator caspase-10 in the form of cell death
triggered by FasL in the presence of zVAD-fmk.
Ectopic expression of wild-type caspase-10 restores FasL-
induced cell death in zVAD-fmk-treated I9-2e cells
To further evaluate the putative role of initiator caspases in
FasL-induced cell death in the presence of zVAD-fmk, wild-type
or catalytically inactive caspase-8 or -10 were expressed in I9-2e
cells and, immediately after transfection, cells were incubated in
the presence of 40 mM zVAD-fmk. Twelve hours post-transfec-
tion, cells were further incubated for 4 hours in the presence or
absence of FasL and analysed by flow cytometry (Fig. 5A).
Whereas, in the presence of zVAD-fmk, no toxicity was induced
by wild-type caspase-8 and caspase mutants, over-expression of
wild-type caspase-10 slightly enhanced annexin-V labelling
(Fig. 5B). Noteworthy was the finding that over-expression of
caspase-10 restored FasL-induced annexin-V labelling in the
presence of zVAD-fmk (Figs. 5B and C). Over-expression of
catalytically inactive mutants failed to sensitize cells to FasL under
our experimental conditions (Fig. 5C). Altogether, our data
provide genetic evidence for the involvement of caspase-10 in
FasL-induced cell death in the presence of zVAD-fmk, which was
previously defined as ‘‘caspase-independent cell death’’. Moreover,
caspase-10 activity appears to be critical for inducing this form of
cell death in response to FasL.
zVAD-fmk does not abrogate caspase-10-triggered
apoptosis
To further evaluate the role of caspase-10 in Fas signalling, we
attempted to perform Western blot analysis of caspase activation
in reconstituted I9-2e Jurkat cells. However, the too low
transfection efficiency of Jurkat cells precluded such analyses.
We therefore used another cell type, i.e., the HeLa carcinoma cell
line, which does express endogenous caspase-8 but not caspase-10
as compared to A3 Jurkat cells (Fig. 6A). HeLa cells could be
efficiently transfected, as illustrated by high percentages of EGFP-
expressing cells sixteen hours post-transfection with a plasmid
Figure 3. Caspase-8 and -10 can restore FasL-induced apoptosis in caspase-8 and -10-doubly deficient Jurkat cells. A, B, I9-2e Jurkat
cells were transiently transfected with plasmids encoding EGFP, EGFP-tagged wild-type caspase-8 or -10 or EGFP-tagged catalytically inactive
caspase-8 mutant (Casp-8 C360S). Alternatively, cells were co-transfected with plasmids encoding EGFP and catalytically inactive caspase-10 mutant
(C401S). Twelve hours post-transfection, cells were further incubated for 4 hours in the presence or absence of 500 ng/mL FasL. Cells were labelled
with annexin-V-APC (AnV-APC). EGFP fluorescence was monitored on untreated cells to determine the percentage of transfected cells (A). Analysis of
annexin-V binding was restricted to the EGFP-expressing cells on both untreated (None) and FasL-treated (FasL) cells (B). Percentages of fluorescent
cells are indicated. Data are from a representative experiment out of three independent experiments. C, Specific cell death triggered by FasL was
calculated by subtracting basal values obtained in the absence of FasL for each transfection. Data are means 6 SEM of three independent
experiments. *p,0.05; **p,0.01.
doi:10.1371/journal.pone.0013638.g003
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caspase expression analysis by Western blot. To evaluate the
caspase-inhibitory efficacy of zVAD-fmk under our experimental
conditions, HeLa cells were transiently transfected with the
different constructs and immediately treated with 40 mM zVAD-
fmk and further incubated for 24 hours. During the last 8 hours,
1 mg/mL FasL was added or not to the cell culture medium. In
cells transfected with plasmids encoding either EGFP-tagged
caspase-8 or -10, an approximately 40 kDa band was revealed
with anti-EGFP antibody (Fig. 6C). The appearance of this band
did not require FasL treatment and most likely corresponded to
the EGFP-tagged small catalytic subunit of pro-caspase-8 and -10,
indicating auto-processing of the over-expressed enzymes (Fig. 6C).
The addition of zVAD-fmk led to a different pattern depending on
the type of EGFP-tagged initiator caspase expressed. Indeed, the
40 kDa band decreased and accumulated in EGFP-tagged
caspase-8 and -10 expressing cells, respectively. In the meantime,
whereas EGFP-tagged pro-caspase-8 strongly accumulated, pro-
caspase-10 accumulation was less pronounced (Figure 6C).
The consequences on endogenous caspase-9 and PARP
cleavage were next analysed under our different experimental
conditions. In the absence of zVAD-fmk, caspase-9 processing (i.e.,
disappearance of pro-caspase-9) occurred upon FasL treatment,
this phenomenon being slightly enhanced in EGFP-tagged
expressing caspase-8 or -10 cells. The addition of zVAD-fmk fully
prevented caspase-9 and PARP cleavage in EGFP and EGFP-
Figure 4. Impairment of FasL-induced cell death in the presence of zVAD-fmk in caspase-8 and -10-doubly deficient Jurkat cells. A,
A3 cells were incubated for the indicated times with 500 ng/mL FasL in the presence (open symbols) or absence (filled symbols) of 40 mM zVAD-fmk.
Caspase activities were assessed using Ac-DEVD-AMC (circles) or Ac-IETD-AMC (triangles). Data are representative of two independent experiments.
B, A3 and I9-2e cells were incubated for 8 hours in the presence or absence of 500 ng/mL FasL and zVAD-fmk (40 mM) as indicated. Cells were fixed
and stained with DAPI before microscopy examination. Arrows indicate cells with partial chromatin condensation. C, D, A3, I9-2d and I9-2e cells were
incubated for 8 hours in the presence of zVAD-fmk (40 mM) with or without 500 ng/mL FasL as indicated. Cells were stained with Annexin-V-FITC
(AnV-FITC) and propidium iodide (PI) and analysed by flow cytometry. Representative flow cytometry experiment out of four independent
experiments (C). Low right quadrants: percentages of [AnV-FITC+ PI-] cells; Up right quadrants: percentages of [AnV-FITC+ PI+] cells; Up left
quadrants: percentages of [AnV-FITC- PI+] cells. D, Percentages of anexin-V-positive (AnV+) cells (means 6 SEM, n=4). **p,0.01.
doi:10.1371/journal.pone.0013638.g004
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finding that caspase-9 and PARP processing was not totally
abrogated in EGFP-tagged caspase-10 expressing cells (Fig. 6C).
Accordingly, whereas zVAD-fmk completely prevented caspase-8-
triggered toxicity, as evaluated by annexin-V labelling, cell death
still occurred in caspase-10 over-expressing cells (Fig. 6D).
Collectively, our data indicate that, whereas zVAD-fmk
potently prevented caspase-8 auto-processing and pro-apoptotic
activity, it had a partial effect on caspase-10 pro-apoptotic
signalling in an over-expression system.
zVAD-fmk does not inhibit caspase-10 processing in Fas
signalling
We then attempted to stably express caspase-10 in HeLa cells at
a physiological level to further evaluate its role in Fas signalling.
HeLa cells transfected with a plasmid encoding EGFP-tagged
wild-type caspase-10 were cultured under G418 for 45 days.
G418-resistant HeLa cells were analysed by flow cytometry and
less than 10% of cells expressed EGFP-tagged caspase-10 at low
levels (Fig. 7A). Indeed, expression was 3 to 4 times lower in stably
than in transiently transfected cells (compare Figs. 6B and 7A).
From this heterogeneous cell population, two cell populations were
FACS sorted based on EGFP expression: EGFP-tagged caspase-10
expressing (Casp10+) HeLa cells and their control counterparts
(Casp10-), which did not express EGFP at all (Fig. 7B). Those were
further grown under G418. This protocol allowed the establish-
ment of Casp10+ HeLa cells, among which 60% of cells stably
expressed EGFP-tagged caspase-10 as evaluated by flow cytometry
(Fig. 7C). Casp10+ and Casp10- HeLa cells displayed similar
CD95, FADD, RIP and caspase-8, -9 and -3 expression as
evaluated by Western blot and flow cytometry (Figs. 7C and D).
Whereas Casp10+ and Casp10- HeLa cells did not express
endogenous caspase-10, Casp10+ HeLa cells expressed exogenous
EGFP-tagged caspase-10 at low level as compared to endogenous
caspase-10 expression in A3 Jurkat cells (Fig. 7D).
Casp10+ HeLa cells and their control counterparts (Casp10-)
were pre-incubated with or without 40 mM zVAD-fmk for one
hour and further incubated in the presence or absence of FasL.
Cell morphology analysis indicated that FasL induced apoptosis
(i.e., nuclear condensation and/or fragmentation) in both cell
lines, caspase-10-proficient cells being slightly, yet not significantly,
more sensitive than caspase-10-null cells (Figs. 8A and B). Addition
of zVAD-fmk fully prevented FasL-triggered cell death in caspase-
10-null HeLa cells. In sharp contrast, apoptotic cell death was not
Figure 5. Caspase-10 can restore FasL-induced cell death in the presence of zVAD-fmk in caspase-8 and -10-doubly deficient Jurkat
cells. A, B, I9-2e Jurkat cells were transiently transfected as described in the legend to Figure 3 and immediately incubated in the presence of 40 mM
zVAD-fmk. Twelve hours post-transfection, cells were further incubated for 4 hours in the presence or absence of 500 ng/mL FasL. Cells were labelled
with annexin-V-APC (AnV). EGFP fluorescence was monitored on untreated cells to determine the percentage of transfected cells (A). Annexin-V
binding analysis was restricted to the EGFP-expressing cells on both untreated (None) and FasL-treated (FasL) cells (B). Percentages of fluorescent
cells are indicated. Data are from a representative experiment out of three independent experiments. Of note, the present data were obtained in the
same experiment depicted in Fig. 3B. C, Specific cell death triggered by FasL was calculated by subtracting basal values obtained in the absence of
FasL for each transfection. Data are means 6 SEM of three independent experiments. **p,0.01.
doi:10.1371/journal.pone.0013638.g005
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(Figs 8A and B). Even at a concentration of 100 mM, zVAD-fmk
failed to abolish cell death in Casp10+ cells (data not shown).
Thus, under our experimental conditions, whereas zVAD-fmk
efficiently prevented FasL-induced apoptosis in caspase-10-defi-
cient HeLa cells, moderate expression of exogenous caspase-10
overcame, to some extent, the resistance conferred by zVAD-fmk.
Western blot analysis further indicated that, in caspase-10-null
cells, FasL triggered endogenous caspase activation, as illustrated
by the decrease of pro-caspase-8 and PARP cleavage (Fig. 8C). In
contrast, FasL promoted no or little decrease of pro-caspase-8 in
caspase-10-expressing HeLa cells. However, EGFP-tagged cas-
pase-10 was efficiently activated as illustrated by the complete loss
of pro-caspase-10 expression and the appearance of the 40 kDa
band, similar to that observed in transiently transfected cells (see
Fig. 6C). PARP was also efficiently cleaved, despite weak
endogenous caspase-8 activation (Fig. 8C). This last observation
may indicate that EGFP-tagged caspase-10 competes with
endogenous caspase-8 to interact with FADD, therefore limiting
the recruitment and activation of endogenous caspase-8 at the
DISC level. Interestingly, whereas zVAD-fmk efficiently blocked
endogenous caspase-8 and PARP processing, it had no or little
effect on EGFP-tagged caspase-10 cleavage (Fig. 8C).
Altogether, our data demonstrate that zVAD-fmk cannot
potently prevent caspase-10 processing in Fas signalling, enabling
the activation of a caspase-10-dependent alternative cytotoxic
signalling pathway in response to FasL.
Discussion
The present observations indicate that the initiator caspase-10 is
involved in FasL-induced cell death and the broad-spectrum
pancaspase inhibitor zVAD-fmk fails to abrogate caspase-10
activity. Indeed, cell death triggered by FasL was fully impaired
in I9-2e (caspase-8 and -10-doubly deficient), but not in I9-2d
(caspase-8-deficient but caspase-10-proficient) Jurkat cells. Cas-
pase-10 expression in I9-2e cells restored sensitivity to FasL.
Moreover, zVAD-fmk did not abrogate FasL-induced toxicity in
Figure 6. zVAD-fmk does not abrogate over-expressed caspase-10-triggered cell death in HeLa cells. A, Total protein extracts derived
from wild-type Jurkat (A3) and HeLa cells were analysed by Western blot using anti-caspase-8, anti-caspase-10 or anti b-actin antibodies. B–D, HeLa
cells were transfected with plasmid encoding EGFP, EGFP-tagged wild-type caspase-8 (Casp8) or -10 (Casp10). B, Cells were analysed by flow
cytometry 16 hours post-transfection. Values indicated are percentages of EGFP-expressing cells. C, Immediately after transfection, 40 mM zVAD-fmk
was added or not to the cell culture medium and cells were further incubated for 24 hours. During the last 8 hours, cells were incubated with or
without 1 mg/mL FasL. Protein extracts were analysed by Western blot using the indicated antibodies. Cleaved PARP expression was analysed at low
(up panel) and high (low panel) exposure. (*: EGFP-tagged pro-caspase-8 or 10, **: EGFP-tagged small catalytic caspase-8 or -10 subunit). The
<26 kDa band obtained in caspase-8 and -10 expressing cells remains to be characterized. D, HeLa cells were transfected and cultured for 24 hours
in the presence or absence of zVAD-fmk. Cells were labelled with annexin-V/APC. Annexin-V binding analysis was restricted to the EGFP-expressing
cells. Data are means 6 SEM of five independent experiments. ***p,0.001; * p,0.05.
doi:10.1371/journal.pone.0013638.g006
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may participate, in addition to the classical pro-apoptotic pathway,
to a zVAD-fmk-resistant alternative cytotoxic pathway mediated
by FasL.
Wild-type A3 Jurkat cells were highly sensitive to FasL (see
Fig. 1C), and dying cells displayed classical features of apoptosis,
including increased specific caspase activity (see Figs. 2A and 4A),
phosphatidylserine externalisation (see Fig. 2A) and nuclear
fragmentation (see Fig. 4B). Whereas caspase-8 and -10-doubly
deficient I9-2e cells were fully resistant to FasL-induced caspase
activation and apoptosis, caspase-8-deficient I9-2d cells, which
expressed caspase-10, displayed an intermediate sensitivity as
compared to I9-2e and A3 cells (see Figs. 1C, 2B and C). This was
associated with a significant increase in specific caspase activity in
I9-2d cells upon treatment by FasL (see Fig. 2A). These data
provide genetic evidence that both endogenous initiator caspase-8
and -10 are involved in FasL-induced caspase-dependent cell
death. Moreover, genetic correction of I9-2e cells either with
EGFP-tagged wild-type caspase-8 or -10 restored FasL-induced
annexin-V labelling, indicating that the resistance of I9-2e cells
was unlikely a ‘‘clone effect’’ and further arguing that both
initiator caspases are indeed involved in Fas apoptotic signalling.
Over-expression of catalytically inactive caspase-8 and -10 in I9-2e
cells slightly increased annexin-V labelling but failed to signifi-
cantly sensitize cells to FasL (see Fig. 3). These findings are in
accordance with recent observations indicating that, under some
experimental conditions, caspase-8 may induce some cytotoxicity
independently of its classical caspase activity [24].
During the last decade, FasL has been reported to trigger a RIP-
dependent alternative form of cell death, exhibiting necrotic rather
than apoptotic features [15]. This alternative form of cell death
was initially defined as a caspase-independent cell death since it
occurred in caspase-8-deficient Jurkat cells and was not sensitive to
the broad-spectrum caspase inhibitor zVAD-fmk [15]. In
accordance with this concept, FasL still triggered some cytotoxicity
in A3 cells in the presence of zVAD-fmk (see Fig. 4D). Most of the
dying cells were doubly labelled with annexin-V and propidium
iodide (see Fig. 4C) and exhibited chromatin alterations with no
Figure 7. Generation of HeLa cells stably expressing EGFP-tagged wild-type caspase-10 at low level. A, HeLa cells were transfected with
plasmid encoding EGFP-tagged wild-type caspase-10 and incubated for 45 days in DMEM 10% FCS containing 0.8 mg/mL G418. The whole
population of cells (Casp10) were analysed by flow cytometry and untransfected HeLa WT cells were used as negative control to determine the
threshold for FL1 channel. Values are percentages of positive cells in FL1 channel. B, Scheme for selection of cells expressing (Casp10+) or not
(Casp10-) EGFP-tagged caspase-10. C, Casp10+ and Casp10- cells were FACS sorted from the heterogeneous population stably expressing caspase-10
and further cultured for one month in DMEM 10% FCS containing 0.8 mg/mL G418 before analysis by flow cytometry for EGFP-tagged caspase-10
and CD95 expression. Values indicated percentages of positive cells in FL1 (up panels) and FL2 (low panels) channels. D, Wild-type Jurkat (A3),
Casp10+ and Casp10- HeLa cells were analysed by Western blot using the indicated antibodies. Caspase-10 expression was analysed at low (up panel)
and high (low panel) exposure. (*: EGFP-tagged pro-caspase-10).
doi:10.1371/journal.pone.0013638.g007
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apoptosis-like or necrosis-like cell death in response to FasL. Of
particular interest was the finding that endogenous caspase-10 was
likely involved in this FasL-induced alternative form of cell death.
Indeed, FasL was unable to kill cells in the presence of zVAD-fmk
in two different caspase-8 and -10-doubly deficient Jurkat clones
(i.e., I9-2e and I9-2a) (see Fig. 4 and data not shown) as well as in
HeLa cells, which did not express endogenous caspase-10 (see
Fig. 8). In marked contrast, I9-2d (i.e., caspase-8-deficient but
caspase-10-proficient) and wild-type A3 Jurkat cells were equally
sensitive towards the combination of FasL and zVAD-fmk (see
Fig. 4). Genetic correction of I9-2e cells with a plasmid encoding
EGFP-tagged caspase-10, but not caspase-8, restored FasL-
induced cell death in the presence of zVAD-fmk (see Fig. 5),
further arguing for a role of caspase-10 in FasL-induced
alternative form of cell death. Caspase-10 activity was required
for its ability to mediate cell death since the expression of a
catalytically inactive caspase-10 (C401S) had no cytotoxic effect.
In addition, FasL-induced cell death was not totally abrogated by
zVAD-fmk in HeLa cells stably expressing caspase-10 at low level
(see Fig. 8).
The broad-spectrum caspase inhibitor zVAD-fmk is commonly
used to study the role of caspases in cell signalling. However, our
findings show that zVAD-fmk is not potent enough to fully inhibit
caspase-10-mediated cytotoxicity. Accordingly, caspase-10 pro-
cessing in Fas signalling still occurred in the presence of zVAD-
fmk (see Figs. 6 and 8). Therefore, in the presence of zVAD-fmk,
the residual protease caspase-10 activity likely promotes an
Figure 8. zVAD-fmk does not totally abrogate FasL-triggered apoptosis in HeLa cells expressing caspase-10 at low level. A, B, Casp10+
and Casp10- HeLa cells were incubated in the presence or absence of 40 mM zVAD-fmk for 1 hour and further incubated for 16 hours with or without
1 mg/mL FasL as indicated. Cells were labelled with Syto13 and propidiumiodide before fluorescence microscopy examination (A). Of note, less than 5%
of the cells were stained by propidium iodide under all conditions indicating that FasL-induced necrosis was marginal in HeLa cells. Percentages of cell
death (i.e., cells exhibiting nuclear fragmentation and/or condensation) were determined by analysing at least 500 cells for each condition. Values are
means 6SEM of three independent experiments (n.s.: not significant; **p,0.01.) (B). C, Casp10+ and Casp10- HeLa cells were incubated in the presence
or absence of 40 mM zVAD-fmk for 1 hour and further incubated for 8 hours with or without 1 mg/mL FasL as indicated. Western blot analysis was
performed using the indicated antibodies. (*: EGFP-tagged pro-caspase-10, **: EGFP-tagged small catalytic caspase-10 subunit).
doi:10.1371/journal.pone.0013638.g008
Caspase-10 in Fas Signalling
PLoS ONE | www.plosone.org 9 October 2010 | Volume 5 | Issue 10 | e13638alternative route of cell death, leading to apoptosis-like cell death.
Thus, experiments based on the use of zVAD-fmk to study the
caspase-independent pathway should be interpreted with caution.
Moreover, our study challenges the existence of an alternative
caspase-independent cell death pathway in Fas signalling.
The previously so-called ‘‘caspase-independent cell death’’
triggeredbydeathreceptorshasbeenreportedtobeRIP-dependent
[15]. One should note that FasL-induced caspase-dependent
apoptosis was slightly, yet significantly, reduced in RIP-deficient
Jurkat cells [25]. Thus, we cannot rule out the possibility that RIP
may functionally interact with caspase-10 to mediate the activation
of an alternative cell death. This hypothesis is strengthened by the
observation that FADD was required for FasL-induced cell death in
the presence of zVAD-fmk [15]. Indeed, whereas FADD deficiency
in Jurkat cells did not impair RIP recruitment to Fas/CD95 in
response to FasL, FADD-deficient Jurkat cells were fully resistant to
both FasL-induced apoptosis and ‘‘caspase-independent cell death’’
[15]. Different groups have previously reported that FADD, besides
its capacity to activate the classical caspase cascade activation, may
also trigger a non-apoptotic form of cell death [26,27,28,29,30].
Interestingly, this non-apoptotic form of cell death occurred in
normal but not in prostate cancer epithelial cells, indicating that this
alternative pathway initiated by FADD may be disrupted in some
cancer cells [29].
Mutations affecting Fas, FasL, caspase-8 or -10 may be
responsible for ALPS or malignancies [2,31,32]. It is tempting to
speculate that some mutations may affect the caspase-10-
dependent cell death pathway, thereby contributing to FasL
resistance in ALPS or in malignant diseases.
Materials and Methods
Reagents
Final concentrations or dilutions of the following reagents are
indicated: zVAD(OMe)-fmk (40 mM) was from Bachem (Voisins-
Le-Bretonneux, France); monoclonal anti-FADD (clone A66-2;
0.5 mg/mL), anti-RIP (clone G322-2, 0.25 mg/mL) and anti-
caspase-8 (clone B9-2; 0.5 mg/mL) antibodies were from BD
Biosciences (Le Pont-de-Claix, France); monoclonal anti-caspase-
10 (clone 4C1; 1 mg/mL) was from MBL (Meudon, France);
polyclonal anti-caspase-3 (10 mg/mL) was from Dako (Trappes,
France); monoclonal anti-caspase-2 (clone C2) and polyclonal anti-
caspase-7, anti-caspase-9, anti-PARP and anti-Bid antibodies were
from Cell Signaling Technology (Saint-Quentin-en-Yvelines,
France) and used at 1/1000 dilution; monoclonal anti-b-actin
(clone AC-15; 5 mg/mL) was from Sigma (Saint-Quentin-Falla-
vier, France); monoclonal anti-CD95 (clone 7C11; 1/5 dilution)
and IgM irrelevant antibody (10 mg/mL) coupled to phycoerythrin
(PE) were purchased from Immunotech (Marseille, France) and
Santa Cruz (Le-Perray-en-Yvelines, France), respectively. cDNAs
encoding wild-type and catalytically inactive mutant caspase-8
(C360S) and wild-type caspase-10 [21] were subcloned into
pEGFP.N1 plasmids. Catalytically inactive mutant caspase-10
(C401S) cDNA [21] was subcloned into pCiNeo plasmid. Plasmids
were kindly given by Dr. M. Lenardo (Bethesda, MD). Mouse
FasL produced in the culture medium of Neuro-2A cells stably
transfected with a plasmid encoding FasL was used at a final
concentration of 500 ng/mL [13,33]. Alternatively, human FasL
kindly provided by Dr. P. Legembre (EA 4427 SeRAIC, Rennes
University, France) was used at a final concentration of 1 mg/mL.
Cell lines
Parental Jurkat T leukaemia cells (clone A3) and the derived cell
line deficient for caspase-8 (clone I9-2) were kindly provided by
Dr. J. Blenis (Boston, MA) [23]. I9-2a, b, d and e cells were
isolated by limiting dilution experiments from I9-2 cells as
previously described [13]. Cells were cultured in RPMI 1640
medium containing Glutamax and 10% heat-inactivated fetal calf
serum (FCS). HeLa cells were from ATCC and cultured in
DMEM medium containing Glutamax and 10% FCS.
Flow cytometry analyses
For studying phosphatidylserine externalization, cells were
labelled with annexin V-FITC (250 ng/mL) and propidium iodide
(12.5 mg/mL) (Immunotech, Marseille, France) for 10 min at 4uC.
Alternatively, cell death of EGFP fluorescent cells was monitored
after labelling with annexin V-APC (250 ng/mL) (Immunotech,
Marseille, France) for 10 min at 4uC.
CD95 cell surface expression was determined after incubation of
cells for 30 min at 4uC with or without anti-CD95-PE or an
irrelevant antibody coupled to PE.
Analyses were performed on a FACScan (Becton Dickinson, Le-
Pont-de-Claix, France) cytometer.
MTT assay
Viability was evaluated by the tetrazolium-based MTT assay.
Cells were seeded in flat-bottom 96-well plates (10
6 cells/mL,
100 mL/well) for 8 hours at 37uC. After 2-hour incubation
with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) (Sigma), formazan crystals were solubilized overnight at
37uC by adding 100 mL of solubilization buffer (HCl 0.01 N, 10%
SDS) and spectrophotometrically quantified (l=590 nm).
Protein extraction, Western blotting analyses and
fluorogenic DEVD and IETD cleavage enzyme assays
For total protein extraction, 5 to 20610
6 cells were lysed for
30 min on ice in a buffer containing 10 mM HEPES (pH 7.4),
42 mM KCl, 5 mM MgCl2, 1 mM DTT, 0.5% CHAPS, 1 mM
PMSF and 2 mg/mL leupeptin. Samples were centrifuged at
10,000 g at 4uC for 10 min. Supernatants were collected and
protein content was determined by the Bradford method (Biorad).
For Western blot analyses, equal amounts of protein were
separated on 15% SDS-PAGE. Caspase activities were assessed
using Ac-DEVD-AMC or Ac-IETD-AMC substrates (Bachem) as
described elsewhere [34].
Morphological analyses
100,000 Jurkat cells were sedimented onto microscope slides by
cytospin at 100 g for 10 min. Cells were fixed by 0.4%
paraformaldehyde, DAPI stained and examined under a fluores-
cence Leica microscope. Alternatively, HeLa cells were labelled
with 2.5 mM Syto 13 (Molecular probes, Leiden, The Netherlands)
and 2 mg/mL propidium iodide (Sigma). The percentage of
apoptotic cells (having nuclear condensation and/or fragmenta-
tion) was evaluated by counting at least 500 cells for each
condition under a Leica fluorescence-equipped inverted micro-
scope as previously described [13].
Transfection experiments
Jurkat cells were transiently transfected as previously described
[35]. Briefly, 2610
6 cells were incubated in 0.2 mL 10 mM
phosphate buffer (pH 7.4) containing 250 mM sucrose and 1 mM
MgCl2. Eight mg of plasmids encoding EGFP, EGFP-tagged wild-
type caspase-8, EGFP-tagged C360S caspase-8 or EGFP-tagged
wild-type caspase-10 were added before electro-pulsation. Alter-
natively, cells were co-transfected by 2 mg of the plasmid encoding
EGFP and 8 mg of the plasmid encoding C401S caspase-10.
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rectangular pulses (240 V, electrode width 4 mm, 1 s delay).
Immediately after pulse delivery, FCS was added to reach a 20%
final concentration and cells were then incubated at 37uCi n2m L
RPMI medium containing 10% FCS. Under these optimized
experimental conditions, 1463% (mean 6 SEM, n=7) of the
Jurkat cells transfected with the plasmid encoding EGFP robustly
expressed EGFP (mean fluorescence intensity =15886150, mean
6 SEM).
HeLa cells were transiently transfected with 8 mg of plas-
mids encoding EGFP, EGFP- tagged wild-type caspase-8 or
EGFP-tagged wild-type caspase-10 using Lipofectamine 2000
(Invitrogen, Cergy Pontoise, France) according to manufacturers’
recommendations.
HeLa cells transfected with EGFP-tagged caspase-10 were
cultured in the presence of 0.8 mg/mL G418 for 45 days. Stably
EGFP-tagged caspase-10 expressing cells (Casp10+ cells) and their
control counterparts (Casp10- cells) were sorted using a FAC-
SARIA-SORP cell sorter and routinely maintained under 0.8 mg/
mL G418.
Statistical analysis
Results are expressed as means 6 SEM of at least three
independent experiments. Mean values were compared using the
Student’s t-test. Differences were considered statistically significant
when p,0.05 (as indicated by an asterisk on the figures; n.s., not
significant).
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